VYNE

Insider Trades

Name	Value	Action	Price	Current Price
Lepore Patrick GDirector $44k15k shares BuyJan 15, 2025 $2.92 --

News

defenseworld.netShort Interest in VYNE Therapeutics Inc. (NASDAQ:VYNE) Decreases By 35.7%defenseworld.netApr 15

Trade VYNE

About VYNE Therapeutics Inc.

VYNE Therapeutics Inc. is a pharmaceutical enterprise dedicated to discovering and advancing therapies for immune-mediated inflammatory conditions. Its development portfolio features FCD105, a topical foam formulation that has successfully finished Phase III clinical studies for the management of moderate-to-severe acne vulgaris. Another candidate in its pipeline is FMX114, a combination treatment incorporating tofacitinib, which is currently in early-stage clinical assessment, referred to as a Phase IIa preclinical trial, for addressing mild-to-moderate atopic dermatitis. Additionally, the company is progressing VYN201, a bromodomain and extra-terminal (BET) inhibitor designed to target a range of immuno-inflammatory disorders, notably those affecting the skin. A further asset is VYN202, which comprises BET inhibitor compounds engineered for selective action on bromodomain 2. Established in 2003, the firm was formerly recognized as Menlo Therapeutics Inc. before officially changing its corporate identity to VYNE Therapeutics Inc. in September 2020. The company's principal operations are based in Bridgewater, New Jersey.

CEO: David T. Domzalski
IPO Date: Jan 25, 2018

Market Data

Open: $0.6267
High: $0.6609
Low: $0.6231
Volume: 222.3K
Avg Volume: 163.6K
52W High: $1.96
52W Low: $0.281

Valuation

Market Cap: $11M
Enterprise Value: $-14M
Dividend Yield: 0.00%

Financials

Free Cash Flow: $-33M
Revenue: $570k
Net Income: $-26M
Cash: $24M
Debt: $0

Events

EarningsAug 13

EPS est. -0.18